Abstract
Prior research suggests that meditation may slow brain aging and reduce the risk of Alzheimer’s disease (AD). However, we lack research systematically examining what aspect(s) of meditation may drive such benefits. In particular, it is unknown how breathing patterns during meditation might influence health outcomes associated with AD. In this study, we examined whether two types of mindfulness meditation practice - one with slow breathing and one with normal breathing – differently affect plasma amyloid beta (Aβ) relative to a no-intervention control group. One week of daily mindfulness practice with slow breathing decreased plasma Aβ levels whereas one week of daily mindfulness practice with normal breathing increased plasma Aβ levels. The no-intervention control group showed no changes in plasma Aβ levels. Slow breathing appears to be a factor through which meditative practices can influence pathways relevant for AD.
Research Transparency Statement Conflicts of interest: All authors declare no conflicts of interest. Funding: This study was supported by Epstein Breakthrough Alzheimer’s Research Fund (PI: Mather, co-PI: Choupan) and by R01AG080652 (PI: Mather). Artificial intelligence: No artificial intelligence assisted technologies were used in this research or the creation of this article. Ethics: This research received approval from the University of Southern California Institutional Review Board (ID: UP-23-00373).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT06210035
Funding Statement
This study was funded by Epstein Breakthrough Alzheimer's Research Fund (PI: Mather, co-PI: Choupan) and by R01AG080652 (PI: Mather).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the University of Southern California gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Kaoru Nashiro, Ph.D. Research Associate Professor nashiro{at}usc.edu
Baruch Rael Cahn, MD, PhD Clinical Associate Professor rael.cahn{at}usc.edu
Paul Choi Project Assistant choipaul{at}usc.edu
Hye Rynn J. Lee Project Assistant hjlee{at}usc.edu
Shaakhini Satchi Research Assistant ssatchi{at}usc.edu
Jungwon Min, Ph.D. Postdoctoral Scientist minjungw{at}usc.edu
Hyun Joo Yoo, Ph.D. Research Scientist hyunjooy{at}usc.edu
Noah Mercer Software Consultant noahmerc{at}usc.edu
Christine Cho Project Manager cho890{at}usc.edu
Lorena Sordo, Ph.D. Postdoctoral Scientist lsordo{at}hs.uci.edu
Elizabeth Head, Ph.D. Professor heade{at}uci.edu
Jeiran Choupan, Ph.D. Assistant Professor choupan{at}usc.edu
Mara Mather, Ph.D. Professor mara.mather{at}usc.edu
The title has been revised, Figures 2 and 3 updated, and minor edits made throughout the manuscript and supplemental information.
Data Availability
All data produced in the present study are available upon publication.
